IDP-121 Concentrate for solution for infusion 3 mg/mL

DRUG2 trials

Sponsors

Idp Discovery Pharma S.L.

Conditions

Any type of B-cell lymphomasChronic lymphocytic leukemia (CLL)Multiple myeloma (MM)Unresectable/metastatic Small cell Lung Cancer (SCLC)

Phase 1

A phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA)

RecruitingCTIS2024-519194-19-00

Idp Discovery Pharma S.L.Any type of B-cell lymphomas, Chronic lymphocytic leukemia (CLL), Multiple myeloma (MM)

Start: 2023-06-06Target: 62Updated: 2024-12-30

Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)

Not yet recruitingCTIS2025-521902-17-00

Idp Discovery Pharma S.L.Unresectable/metastatic Small cell Lung Cancer (SCLC)

Target: 60Updated: 2025-12-18